This is a preview of subscription content, log in via an institution to check access.
REFERENCES
Chouinard, G., Jones, B., Remington, G., Bloom, D., Addington, D., MacEwan, G. W., Labelle, A., Beauclaire, L., & Arnott, W. (1993). A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenia. Journal of Clinical Psychopharmacology, 13, 5–40.
Cook, E. H., Jr., Rowlett, R., Jaselskis, C., & Leventhal, B. L. (1992). Fluoxetine treatment of children and adults with autistic disorder and mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 739–745.
Feeney, D. J., & Klykylo, W. (1996). Risperidone and tardive dyskinesia. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 1421–1422.
Gordon, C. T., State, R. C., Nelson, J. E., Hamburger, S., & Rapoport, J. L. (1993). A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Archives of General Psychiatry, 50, 441–447.
Grant, S., & Fitton, A. (1994). Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs, 48, 253–273.
Hardan, A., Johnson, K., Johnson, C., & Hrecznyj, B. (1996). Case study: Risperidone treatment of children and adolescents with developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 1551–1556.
Horrigan, J. P., & Barnhill, L. J. (1997). Risperidone and explosive aggressive autism. Journal of Autism and Developmental Disorders, 27, 313–323.
Kumra, S., Herion, D., Jacobsen, L. K., Briguglia, C., & Grothe, D. (1997). Case study: Risperidone-induced hepatotoxicity in pediatric patients. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 701–705.
Leysen, J. E., Janssen, P. M. F., Megens, A. A. H. P., & Schotte, A. (1994). Risperidone: A novel antipsychotic with balanced serotonin-dopamine antagonism. receptor occupancy profile, and pharmacologic activity. Journal of Clinical Psychiatry, 55 (5, Suppl.), 5–12.
McDougle, C. J., Brodkin, E. S., Yeung, P. P., Naylor, S. T., Cohen, D. J., & Price, L. H. (1995). Risperidone in adults with autism or pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology, 34, 273–282.
McDougle, C. J., Holmes, J. P., Bronson, M. R., Anderson, G. M., Volkmar, F. R., Price, L. H., & Cohen, D. J. (1997). Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective open-label study. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 685–693.
McDougle, C. J., Naylor, S. T., Cohen, D. J., Volkmar, F. R., Heninger, G. R., & Price, L. H. (1996). A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry, 53, 1001–1008.
Purdon, S. E., Lit, W., Labelle, A., & Jones, B. D. (1994). Risperidone in the treatment of pervasive developmental disorder. Canadian Journal of Psychiatry, 39, 400–405.
Simon, E. W., Blubaugh, K. M., & Pippidis, M. (1996). Substituting traditional antipsychotics with risperidone for individuals with mental retardation. Mental Retardation, 34, 359–366.
Touchette, P. E., MacDonald, R. F., & Langer, S. N. (1985). A scatter-plot for identifying stimulus control of problem behavior. Journal of Applied Behavior Analysis, 18, 343–351.
Vanden Borre, R., Buttiens, M., Thiry, P., Geutjens, J., Sieben, G., & Heylen, S. (1993). Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind, cross-over study. Acta Psychiatrica Scandinavia, 87, 167–171.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dartnall, N.A., Holmes, J.P., Morgan, S.N. et al. Brief Report: Two-Year Control of Behavioral Symptoms with Risperidone in Two Profoundly Retarded Adults with Autism. J Autism Dev Disord 29, 87–91 (1999). https://doi.org/10.1023/A:1025926817928
Issue Date:
DOI: https://doi.org/10.1023/A:1025926817928